DP20

DP20 is an early-stage research project currently under development by Damian Pharma. As of early 2024, the specific therapeutic target, molecular modality, and primary disease indication for DP20 have not been publicly disclosed by the company. The project is notable for having received research grants from Innosuisse, the Swiss Innovation Agency, in 2020 and 2022, which indicates that the asset is likely in the discovery or preclinical stage. Damian Pharma's broader pipeline is centered on cardiovascular and endocrine disorders, particularly Primary Aldosteronism, though it remains unconfirmed if DP20 is intended for these therapeutic areas.